# Prospective Observational Study to Describe Characteristics and Management of Patients Treated With Denosumab (Prolia®) in Routine Clinical Practice

> **NCT01652690** · — · COMPLETED · sponsor: **Amgen** · enrollment: 600 (actual)

## Conditions studied

- Osteoporosis, Postmenopausal

## Interventions

- **BIOLOGICAL:** Denosumab

## Key facts

- **NCT ID:** NCT01652690
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2012-06-26
- **Primary completion:** 2015-05-15
- **Final completion:** 2015-05-15
- **Target enrollment:** 600 (ACTUAL)
- **Last updated:** 2019-03-06

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01652690

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01652690, "Prospective Observational Study to Describe Characteristics and Management of Patients Treated With Denosumab (Prolia®) in Routine Clinical Practice". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01652690. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*